isvma 2017 november 2017...myoclonic atonic cluster seizures status epilepticus kitz et al. j vet...
TRANSCRIPT
-
ISVMA 2017 November 2017
DR. MICHAEL PODELL 1
Michael Podell MSc, DVMDiplomate ACVIM (Neurology)
MedVet [email protected]
773‐281‐7110
PURPOSE To provide 10 guiding principles to the diagnosis and management of an epileptic cat to improve treatment outcome measures
Successful treatment is dependent upon the 3 “D”s: Diagnosis Drug selection Dose administration
Update on novel theories on etiology Update on treatment strategies Update on the International Veterinary Epilepsy Task Force (IVETF) Consensus Statement
International Veterinary Epilepsy Task Force
The International Veterinary Epilepsy TaskForce (IVETF) is formed by a mondial (among others Europe, United States of America, Australia) group of (veterinary) scientists interested and specialised in the field of epilepsy. Our group consists of clinical veterinary neurologists, neuropharmacologists, and veterinary neuropathologists http://www.ivetf.org/
PRINCIPLE #1:THE BRAIN IS SIMILAR TO OTHER
ORGANS IN THE BODY Signs parallel severity of illness
Resiliency Responsive to therapy
PRINCIPLE #2:BE CERTAIN THAT AN EPILEPTIC SEIZURE HAS
OCCURRED Positive diagnosis is essential prior to therapy Epileptic seizures: Paroxysmal onset, finite duration, +/‐ post‐ictal changes
Diagnosis of epilepsy = abnormal brain function
-
ISVMA 2017 November 2017
DR. MICHAEL PODELL 2
SEIZURE TYPES Focal (partial)
Sensory (psychic) Motor
Elementary Automatisms
Orofacial pain syndromes
Generalized Tonic‐clonic Clonic Myoclonic Atonic
Cluster seizures Status Epilepticus
Kitz et al. J Vet Intern Med. 2017 31(3): 633–640.
Feline Audiogenic Reflex SeizuresLowrie et al J Feline Med and Surg (2016) 18:328‐336
Seizures precipitated by sound High pitched (metal clinking, tin foil
Repetitive (computer keys, phone ring)
Myoclonic seizurespredominant type (94%)
Normal diagnostic testing Treatment
Levetiracetam (93% success for myoclonic seizures)
Avoidance (dec by 75%)
PRINCIPLE #3: IDENTIFY THE SEIZURE ETIOLOGY
SEIZURE ETIOLOGY CLASSIFICATION
PRIMARY
SYMPTOMATIC
PROBABLE SYMPTOMATIC
EPILEPSY REACTIVE
RECURRENT
PRIMARY
SYMPTOMATIC
REACTIVE
NON-RECURRENT
EPILEPTIC SEIZURE NON-EPILPETIC SEIZURES
SEIZURE
PREVALENCE BY ETIOLOGYSTUDY TOTAL
NUMBERIDIOPATHIC SYMPTOMATIC METABOLIC
/ TOXIC
Barnes et alJAVMA 2004
17 7 7 3
Schriefl et alJAVMA 2008
91 23 45 20
Pakozdy et alJ Feline Med Surg 2010
125 47 70 8
TOTALS 233 77 (35%) 122 (52%) 31 (13%)
IDIOPATHIC (PRIMARY) EPILEPSY Normal brain structure with abnormal function
Less common than in dogs Age of onset typically
-
ISVMA 2017 November 2017
DR. MICHAEL PODELL 3
SYMPTOMATIC CAUSES Infectious
FIP Protozoal
Neoplasia Meningioma
Vascular Head trauma
80% Post‐ligation: >35%
Lipscomb et al Vet Rec 2007 Toxicity
Permethrin Nutritional
Thiamine depletion Cardiogenic
A‐V block May not be syncopal
Feline Hippocampal Necrosis Syndrome
Adult cats with high frequency seizure activity
Histopathologic evidence of selective hippocampal necrosis
Difficult to treat cases
Temporal Lobe Epilepsy in People Anatomy
Neocortex (6 layer) Hippocampus (3 layer) Subcortical nuclei
Complex partial seizures Ambulatory automatisms Hallucinatory phenomenon
Hippocampal sclerosisHighest degree of medically intractable epilepsy
Scharfman and Pedley, 2007
-
ISVMA 2017 November 2017
DR. MICHAEL PODELL 4
Limbic Encephalitis Autoimmune disease in adult people
CSF autoantibody Onconeuronal Voltage‐gated potassium channels
MRI scan of hyperintense hippocampal lesions on T2W and FLAIR images
Normal CSF analysis Progression to temporal lobe epilepsy and hippocampal sclerosis
Treatment of primary disease may prevent need for chronic antiepileptic drug therapy
23 yo woman Bien et al Neurol 2007;69:1236-1244
Feline Limbic Encephalitis
35 yo man with hippocampalsclerosis and LE
6 yo MC DSH cat with refractory epilepsy
Bien et al Neurol 2007;69:1236-1244Podell and Oglesbee 2008 2/10 cats with serum & CSF VGKC AB
Pakozdy et al JVIM 20135/14 cats with serum VGKC AB
PRINCIPLE #4:ALWAYS TREAT THE UNDERLYING DISEASE Antiepileptic drug therapy manages the signs ONLY
Reversal of metabolic abnormalities often prevents the need for chronic AED therapy
Symptomatic epilepsy may still need to be treated with AEDs despite removal of the inciting cause
PRINCIPLE #5:“SEIZURES BEGET SEIZURES”
William Gowers Accurate history and documentation is essential
The earlier AED therapy is started, the better the potential outcome for seizures control
Earlier therapy may reduce the need for multiple drug therapy
Kindling Progression of clinical and EEG seizures induced by repeated activation in neural pathways
Critical period exists (
-
ISVMA 2017 November 2017
DR. MICHAEL PODELL 5
Realistic Expectations by Owners Life‐long commitment
Daily medication commitment
Potential for emergency treatment
Inherent risks of therapy
Time for another pill?!!
Reasons to Start Antiepileptic Drug Therapy Identifiable structural lesion present (symptomatic epileptic seizures)
Status epilepticus has occurred
More than 3 generalized seizures occurred within a 24 hour period
Reasons to Start Antiepileptic Drug Therapy
Two or more cluster seizure events (2 or more seizures) occur within a 12 month period
Two or more isolated seizure events occur within a 6 month period
The first seizure is within 6 months of head trauma
Prolonged, severe, or unusual post‐ictal periods occur
PRINCIPLE #6:Start with the Appropriate AED
First Generation Phenobarbital Benzodiazepines Bromide
Second Generation Levetiracetam Zonisamide TopiramateGabapentin
IVETF Recommendations
High • Phenobarbital• Levetiracetam
Moderate• Zonisamide• Diazepam• Gabapentin• Pregabalin
Low
• Clonazepam• Topiramate• Propentofylline• Taurine
PHENOBARBITAL EfficaciousWell‐tolerated Consistent in its effect Can be monitored Can be given as an injectable or oral formulation
Relatively rapid acting Can serve as a cerebral protectant
Inexpensive
Phenobarbital Is the Drug of Choice for the
Majority of Cases
-
ISVMA 2017 November 2017
DR. MICHAEL PODELL 6
PHENOBARIBITAL TREATMENT PEARLS
2.5 mg/kg PO daily at night to start Elimination half‐life 34‐43 hours
No hepatic enzymeautoinduction
IV loading dose: Total mg IV = (Body weight [kg] X (0.8 L/kg) X 10 ug/ml)
= 8 mg/kg over 3 minutes Therapeutic range: 10‐50 mg/dl
Hepatot0xicity is very rare
POTASSIUM BROMIDE PEARLS
Not recommended for use in cats due to potential for allergic bronchitis syndromewhich can be fatal
PRINCIPLE # 7:MONITOR AED CONCENTRATIONS(Be Proactive Rather Than Reactive) Determine if therapeutic level present at lowest daily time point (trough)
Document steady‐state concentration
Prevent toxic effects
Individualize therapy
PHENOBARBITAL MONOTHERAPY Range:
Initial goal is 15‐20 mg/dl Maximum: 50 mg/dl
Measure at: Trough times 14, 45, 90, 180, and 360 days after the initiation of treatment
At 6 months intervals thereafter If pet has more than two seizure events between these times
14 days after the last dosage adjustment
Benzodiazepine Therapy Diazepam
Oral: 2.5 to 5 mg q 12 hours
IV: 0.5 mg/kg bolus CRI IV: 0.25 mg/kg/hrin saline
Per rectal: Not recommended
Clonazepam Oral: 0.25 to 0.5 mg q 12‐24 hours
Evaluate liver panel 2 weeks post‐chronic treatment for idiosyncratic hepatic necrosis
PRINCIPLE # 8:KNOW HOW AND WHEN TO ADJUST AED DOSAGE
Weight based dosing used on initial therapy only Follow established therapeutic serum concentration ranges Adjust after steady‐state concentrations achieved Adjust for metabolic tolerance Gradual increments are most effective
TOLERANCE= LOSS OF EFFECTIVENESSTOLERANCE= LOSS OF EFFECTIVENESSACQUIREDACQUIRED
POSITIVEPOSITIVE NEGATIVENEGATIVE
METABOLICMETABOLIC FUNCTIONALFUNCTIONALUP
REGULATION OF
RECEPTORS
UP REGULATION
OF RECEPTORS
ENZYME INDUCTION
ENZYME INDUCTION
CROSS- TOLERANCE
CROSS- TOLERANCE
DOWN REGULATION
OF RECEPTORS
DOWN REGULATION
OF RECEPTORS
DECREASED BBB
DELIVERY
DECREASED BBB
DELIVERY
PROGRESSION OF DISEASE
PROGRESSION OF DISEASE
TIMETIME
DOSE[SERUM]
-
ISVMA 2017 November 2017
DR. MICHAEL PODELL 7
Phenobarbital Dose Adjustments Monitor trough serum concentrations
Consistent time point for comparison Time period of highest risk for relapse Comparison to peak levels for toxicity
New total mg phenobarbital per day= (desired concentration / actual concentration) X total mg per day
Differential dosing for animals with more frequent night/early AM seizures
PRINCIPLE # 9:CHECK ON OWNER COMPLIANCE Seizure records Review of dosing schedule and method 20% drop of trough steady‐state concentration can be an indicator of poor compliance
MONTH 1 MONTH 2 MONTH 3
DAY 1 SEIZURE #
DAY 2
DAY 3
SINGLESHEETRECORDFOR 1YEARTOTAL
PRINCIPLE # 10:KNOW WHEN TO ADD, CHANGE, OR
STOP MEDICATIONS Reasons for adjustments
Refractory epilepsy: Recurrent seizure activity at a rate of > 1 per 8 weeks
Toxicities Expense
Discontinuation is always a gamble Higher probability of success with longer history of control
Gradual reductions are important to avoid withdrawal seizures IVETF BMC Vet Res. 2015; 11: 177.
LEVETIRACETAMPHARMACOKINETICS
Low protein binding results in minimal drug interactions
Renal excreted (70%) Minimal hepatic metabolism
Elimination half‐life of 2.9 hr (1.9‐19.6 range) Bailey et al JAVMA 2008:232: 867‐872
Pharmacodynamic effect > pharmacokinetic effect
-
ISVMA 2017 November 2017
DR. MICHAEL PODELL 8
LEVETIRACETAM TREATMENT
Primary drug Liver disease or older cats Dose: 20 mg/kg po TID with gradual up‐titration
Best add‐on drug Best tolerated of all new AED in cats Excellent add‐on option for all seizure types Dose: Dose: 20 mg/kg po TID with gradual up‐titration
Best used with orofacial complex partial seizures/pain syndrome
Monitoring drug levels not recommended due to high therapeutic index
Maximal dose: 50 mg/kg PO TID or adverse effects
ZONISAMIDE
ZONISAMIDE Blocks Na+ and Ca+2 channels to reduce depolarization
Long elimination half‐life of 30 + hours
Dose 5 mg/kg/day 25, 50, 100 mg capsules
Therapeutic range 10‐40 mcg/ml
Metabolic acidosis prevalent
Wahle AM et al JVIM 2014 28(1): 182-188
PROGNOSISEPILEPSY OF UNDETERMINED CAUSE
SYMPTOMATIC EPILEPSY
4 mo
“SAPERE VADERE”